Our take
Omnicell offers IV compounding robots, semi-automated IVX Workflow software, and an IV Compounding Service that combines robots, analytics, and onsite experts so hospitals can compound more IV doses in house.1
It suits health systems that want to cut outsourcing and buy IV automation as a managed service. Allegheny General Hospital reports $1.5 million in annual savings.1
Scores by criterion
Pricing transparency, 3.0: Omnicell publishes no prices; the IV Compounding Service is sold as a partnership with shared objectives.1
Product maturity, 7.5: The IV room line spans robotics, smart devices, software, and services.1
Deployment evidence, 7.5: Omnicell cites Allegheny General Hospital, which saved $1.5 million a year by reducing outsourcing and operating room waste.1
Company durability, 8.5: Omnicell revenue was $1.185 billion in 2025, up 7 percent.2
Ease of integration, 7.0: The service model includes onsite and remote experts, which eases rollout but ties the hospital to Omnicell.1
Each criterion is defined on our methodology page.
Who uses Omnicell and what it's for
The buyer is a hospital or health system pharmacy that compounds IV doses and wants to bring more of that work in house.1
IV room automation
The IV room line combines compounding robots, IVX Workflow for semi-automated compounding, and the IV Compounding Service.1,3
Pricing
Omnicell quotes IV room systems and services by contract.1
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where Omnicell wins or loses |
|---|---|---|---|---|
| Omnicell | IV compounding robots, IVX Workflow software, IV Compounding Service1 | Service contracts; by quote1 | Allegheny General saves $1.5 million a year1 | Pharmacy automation group; above band |
| ARxIUM | RIVA IV robot plus packagers, cabinets, and inventory software4 | Not published; consultation12 | More than 19 million RIVA doses5 | ARxIUM wins on RIVA IV compounding robots with a long record. Omnicell wins on IV automation sold as a managed service. |
| EQUASHIELD Pro | Automated hazardous drug compounder using closed transfer devices7 | Not published; quote7 | Equashield sells on five continents8 | Equashield wins on closed-system compounding for hazardous drugs. Omnicell wins on IV automation sold as a managed service. |
| KIRO Oncology | Two-arm hazardous drug compounder with gravimetric checks9 | Not published; quote9 | Part of the inclusiv IV compounding portfolio13 | Kiro wins on automated compounding for chemotherapy. Omnicell wins on IV automation sold as a managed service. |
| Loccioni APOTECAchemo | APOTECAchemo IV chemotherapy compounding robot11 | Not published11 | User community across the US, Europe, the Gulf, and Asia11 | APOTECA wins on oncology compounding robots from Italy. Omnicell wins on IV automation sold as a managed service. |
Limits
Revenue far above our usual band.2
No published prices.1
Service contracts tie hospitals to one vendor.1
What customers say
Where it helps
IV compounding automation sold as a managed service.1
Where it falls short
Contract pricing only.1
Company backing
Omnicell is listed on NASDAQ. Founder Randall Lipps is chairman, president, and chief executive officer.2
Sources
- Omnicell, IV room solutions, accessed November 16, 2026
- Omnicell, Fiscal year and fourth quarter 2025 financial results, accessed November 16, 2026
- Omnicell, IVX Workflow, accessed November 16, 2026
- ARxIUM, RIVA robotic IV automation and compounding systems, accessed November 10, 2026
- ARxIUM, News and events hub, accessed November 10, 2026
- ARxIUM, Our headquarters, accessed November 10, 2026
- Equashield, EQUASHIELD Pro automated compounding of hazardous drugs, accessed November 10, 2026
- Nordic Capital, Equashield portfolio company profile, accessed November 10, 2026
- Kiro Grifols, KIRO Oncology, accessed November 10, 2026
- Grifols, Grifols reports revenues of EUR 7,524m, up 7% (February 26, 2026), accessed November 10, 2026
- Loccioni, Apoteca Community, accessed November 10, 2026
- ARxIUM, homepage, accessed November 10, 2026
- Kiro Grifols, Robotic and other compounding devices, accessed November 10, 2026

